Premium
Nanoceria‐Triggered Synergetic Drug Release Based on CeO 2 ‐Capped Mesoporous Silica Host–Guest Interactions and Switchable Enzymatic Activity and Cellular Effects of CeO 2
Author(s) -
Xu Can,
Lin Youhui,
Wang Jiasi,
Wu Li,
Wei Weili,
Ren Jinsong,
Qu Xiaogang
Publication year - 2013
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201200464
Subject(s) - mesoporous silica , nanoparticle , internalization , a549 cell , mesoporous material , intracellular , drug delivery , biophysics , cancer cell , chemistry , materials science , nanotechnology , chemical engineering , organic chemistry , cell , biochemistry , catalysis , cancer , medicine , biology , engineering
Herein, a pH stimuli‐responsive vehicle for intracellular drug delivery using CeO 2 capped mesoporous silica nanoparticles (MSN) is reported. β‐Cyclodextrin‐modified CeO 2 nanoparticles could cap onto ferrocene‐functionalized mesoporous silica through host–guest interactions. After internalization into A549 cells by a lysosomal pathway, the ferrocenyl moieties are oxidized to ferrocenium ions by CeO 2 lids, which could trigger the uncapping of the CeO 2 and cause the drugs release. Because of the pH‐dependent toxicity, the CeO 2 here behaves as a multi‐purpose entity that not only acts as a lid but also exhibits a synergistic antitumor effect on cancer cells. Meanwhile, the cell protective effect of CeO 2 nanoparticles alone is demonstrated, which ensures that the dissolved CeO 2 nanoparticles can be non‐toxic to normal cells.